Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Gives Metabolism/Endocrinology Division An Acting Director

This article was originally published in The Pink Sheet Daily

Executive Summary

Diabetes team leader Jean-Marc Guettier is detailed to replace Mary Parks as director of the Division of Metabolism and Endocrinology Products on a temporary basis as she moves up to Deputy Director of the Office of Drug Evaluation II.


Related Content

ANCHOR Indication For Amarin’s Vascepa Will Face FDA Panel Scrutiny
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs
Amarin Aims Vascepa For The Sweet Spot Of Dyslipidemia
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts